Tap Water Colonization With Psmdomonas aeruginosa in a Surgical Intensive Care Unit (ICU) and Relation to Psmdomonas Infections of ICU Patients

2001 ◽  
Vol 22 (1) ◽  
pp. 49-52 ◽  
Author(s):  
Matthias Trautmann ◽  
Thomas Michalsky ◽  
Heidemarie Wiedeck ◽  
Vladan Radosavljevic ◽  
Markus Ruhnke

AbstractWater faucets on a surgical intensive care ward were examined prospectively as a source of Pseudomonas aeruginosa infections. All water outlets harbored distinct genotypes of P aeruginosa over prolonged time periods. Over a period of 7 months, 5 (29%) of 17 patients were infected with P aeruginosa genotypes also detectable in tap water.

1984 ◽  
Vol 5 (9) ◽  
pp. 427-430 ◽  
Author(s):  
M. Anita Barry ◽  
Donald E. Craven ◽  
Theresa A. Goularte ◽  
Deborah A. Lichtenberg

Abstract During a recent investigation in our surgical intensive care unit, we found that several bottles of the antiseptic handwashing soap, OR Scrub®, were contaminated with Serratia marcescens. OR Scrub® contains 1% triclosan, lanolin, and detergents. The antimicrobial efficacy of OR Scrub® was examined in vitro using serial two-fold dilutions of soap inoculated with various concentrations of different nosocomial pathogens. The minimal bactericidal concentration (MBC) of OR Scrub® against Pseudomonas aeruginosa and several strains of S. marcescens was ≤1:2 By comparison, a non-antiseptic soap from the same manufacturer (Wash®) and 4% chlorhexidine (Hibiclens®) had MBCs for all strains tested of at least 1:64. Time-kill curves confirmed the findings of the initial experiments.This is the first report of extrinsic contamination of antiseptic soap containing triclosan. No infections could be attributed to the contaminated soap, but sporadic outbreaks of Serratia have occurred in the intensive care unit with no identifiable source. Although there have been few studies on the impact of antiseptic soap in reducing nosocomial infection, we question whether a soap with the limitations of OR Scrub® should be used in intensive care units or operating rooms.


2016 ◽  
Vol 23 (2) ◽  
pp. 360-364 ◽  
Author(s):  
Tara Ann Collins ◽  
Matthew P Robertson ◽  
Corinna P Sicoutris ◽  
Michael A Pisa ◽  
Daniel N Holena ◽  
...  

Introduction There is an increased demand for intensive care unit (ICU) beds. We sought to determine if we could create a safe surge capacity model to increase ICU capacity by treating ICU patients in the post-anaesthesia care unit (PACU) utilizing a collaborative model between an ICU service and a telemedicine service during peak ICU bed demand. Methods We evaluated patients managed by the surgical critical care service in the surgical intensive care unit (SICU) compared to patients managed in the virtual intensive care unit (VICU) located within the PACU. A retrospective review of all patients seen by the surgical critical care service from January 1st 2008 to July 31st 2011 was conducted at an urban, academic, tertiary centre and level 1 trauma centre. Results Compared to the SICU group ( n = 6652), patients in the VICU group ( n = 1037) were slightly older (median age 60 (IQR 47–69) versus 58 (IQR 44–70) years, p = 0.002) and had lower acute physiology and chronic health evaluation (APACHE) II scores (median 10 (IQR 7–14) versus 15 (IQR 11–21), p < 0.001). The average amount of time patients spent in the VICU was 13.7 + /–9.6 hours. In the VICU group, 750 (72%) of patients were able to be transferred directly to the floor; 287 (28%) required subsequent admission to the surgical intensive care unit. All patients in the VICU group were alive upon transfer out of the PACU while mortality in the surgical intensive unit cohort was 5.5%. Discussion A collaborative care model between a surgical critical care service and a telemedicine ICU service may safely provide surge capacity during peak periods of ICU bed demand. The specific patient populations for which this approach is most appropriate merits further investigation.


2009 ◽  
Vol 24 (4) ◽  
pp. 625.e9-625.e14 ◽  
Author(s):  
Guilherme H.C. Furtado ◽  
Maria D. Bergamasco ◽  
Fernando G. Menezes ◽  
Daniel Marques ◽  
Adriana Silva ◽  
...  

2020 ◽  
Vol 11 ◽  
pp. 117955732095122
Author(s):  
Chelsea N Lopez ◽  
Amaris Fuentes ◽  
Atiya Dhala ◽  
Jonathan Balk

In intensive care unit (ICU) patients, delirium contributes to prolonged hospitalization, long-term cognitive impairment and increased mortality. Sleep disturbance, a risk factor for delirium, has been attributed to impaired melatonin secretion in critically ill patients. Ramelteon, a synthetic melatonin receptor agonist, is indicated for insomnia; there is limited, but growing evidence, to support its use for the prevention of delirium. The primary objective of this study is to describe the use of ramelteon and the incidence of delirium, assessed by Confusion Assessment Method for the ICU (CAM-ICU) scores, in adult surgical ICU patients from May 22, 2016 to June 30, 2018. The primary endpoint is the number of delirium free days in the week prior to and post first ramelteon administration. A total of 231 patients were included in the study with 201 (87%) positive for delirium at least once during the study timeframe. The median number of CAM-ICU negative days in the week pre-ramelteon administration was 4 days (IQR 2-7 days) compared to 6 days (IQR 3-7 days) in the week post-first ramelteon administration ( P < .05). The time to CAM-ICU positive increased slightly to 3 days (IQR 1-7 days) following ramelteon initiation compared to 2 days (IQR 1-5 days) from initial ICU admission. Additionally, the median number of antipsychotic doses per patient decreased from 4 doses (IQR 1.25-14 doses) prior to ramelteon to 2 doses (IQR 1-4 doses) after ramelteon. Ramelteon administration was associated with a greater number of CAM-ICU negative days in surgical ICU patients. These findings describe a potential role for ramelteon in mitigating delirium in this patient population.


2016 ◽  
Vol 37 (5) ◽  
pp. 544-548 ◽  
Author(s):  
Anthony D. Harris ◽  
Sarah S. Jackson ◽  
Gwen Robinson ◽  
Lisa Pineles ◽  
Surbhi Leekha ◽  
...  

OBJECTIVETo determine the prevalence of Pseudomonas aeruginosa colonization on intensive care unit (ICU) admission, risk factors for P. aeruginosa colonization, and the incidence of subsequent clinical culture with P. aeruginosa among those colonized and not colonized.METHODSWe conducted a cohort study of patients admitted to a medical or surgical intensive care unit of a tertiary care hospital. Patients had admission perirectal surveillance cultures performed. Risk factors analyzed included comorbidities at admission, age, sex, antibiotics received during current hospitalization before ICU admission, and type of ICU.RESULTSOf 1,840 patients, 213 (11.6%) were colonized with P. aeruginosa on ICU admission. Significant risk factors in the multivariable analysis for colonization were age (odds ratio, 1.02 [95% CI, 1.01–1.03]), anemia (1.90 [1.05–3.42]), and neurologic disorder (1.80 [1.27–2.54]). Of the 213 patients colonized with P. aeruginosa on admission, 41 (19.2%) had a subsequent clinical culture positive for P. aeruginosa on ICU admission and 60 (28.2%) had a subsequent clinical culture positive for P. aeruginosa in the current hospitalization (ICU period and post-ICU period). Of these 60 patients, 49 (81.7%) had clinical infections. Of the 1,627 patients not colonized on admission, only 68 (4.2%) had a subsequent clinical culture positive for P. aeruginosa in the current hospitalization. Patients colonized with P. aeruginosa were more likely to have a subsequent positive clinical culture than patients not colonized (incidence rate ratio, 6.74 [95% CI, 4.91–9.25]).CONCLUSIONSPrediction rules or rapid diagnostic testing will help clinicians more appropriately choose empirical antibiotic therapy for subsequent infections.Infect Control Hosp Epidemiol 2016;37:544–548


Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 3637-3637
Author(s):  
Donald M. Arnold ◽  
Laura A. Molnar ◽  
Mark A. Crowther ◽  
Christopher Sigouin ◽  
Julie Carruthers ◽  
...  

Abstract Background: The benefits and harms of platelet transfusions in critically ill patients are unclear. Objectives: To describe the frequency of, indications for, and effects of platelet transfusions in patients admitted to a medical- surgical intensive care unit (ICU). Design: Single center cohort study (January 2001 to January 2002). Methods: We identified all patients who developed thrombocytopenia (platelet count <150 x 109/l) during their ICU admission from a prospective study which enrolled consecutive adults admitted to ICU with an expected length of stay ≥72 hours, and which excluded patients with trauma, orthopedic surgery, cardiac surgery, pregnancy, or receiving palliative care. Retrospectively, using a priori criteria, bleeding severity and the indications for platelet transfusions were assessed; 23.7% of bleeding events and 89.5% of transfusion indications were reviewed in duplicate independently. Initial agreement was calculated using Cohen’s unweighted kappa and all assessments of bleeding severity and transfusion indications were adjudicated by third person. Results: Of 261 ICU patients, 118 (45.2%) had thrombocytopenia. Initial agreement between primary reviewers for assessments of bleeding severity was good (k= 0.69), and for indications for platelet transfusions was poor (k=0.35); consensus was achieved in all cases. One third of thrombocytopenic patients had major bleeding (37/118, 31.4%), and one fifth had minor bleeding (24/118, 20.3%). Among thrombocytopenic patients, 27/118 (22.9%) received a total of 76 platelet transfusions, 24 (31.6%) of which were administered to treat bleeding, and 52 (68.4%) of which were to prevent bleeding. Of the prophylactic platelet transfusions, 18/52 (34.6%) preceded invasive procedures. The mean ± SD platelet count prior to therapeutic platelet transfusions was 54 ± 40 x109/l; for peri-procedural transfusions, 55 ± 38 x109/l; and for other prophylactic platelet transfusions, 37 ± 21 x109/l. Most transfusions (69/76, 91%) were administered as pools of 5.2 ± 1.2 random donor platelets, and few (7/76, 9.2%) were apheresis platelets. A single platelet transfusion (pool of 5 random donor units or 1 apheresis unit) resulted in a platelet increment of 14 ± 29 x109/l at 6.6 ± 5.9 hours following transfusion. No rise in platelet count was observed following 17 transfusions given to 13 patients. Conclusions: Platelet transfusions are frequently administered to thrombocytopenic critically ill patients, and, although the indication is not always clear, the most common reason is to prevent bleeding. Nearly half of transfused ICU patients were refractory to one or more platelet transfusion. Further prospective studies are needed on the indications for, and effects of, platelet transfusions in the ICU setting.


Sign in / Sign up

Export Citation Format

Share Document